
Feature: Chinese experts assist Myanmar quake survivors with vital public health aid
MANDALAY, Myanmar, May 11 (Xinhua) -- Sitting outside a tent donated by China, 35-year-old Nyo Nyo Lwin said the China Public Health Team came and provided vaccines, added water disinfectants to the domestic water pots, and checked if the food preparation was safe.
"I'm very grateful to them," Nyo Nyo Lwin said. "My husband and I still can't return to work. The stone carving business he had worked was hit hard by the quake."
Their family now lives with two elderly relatives, both over 80 years old. "We only rely on donations now, including tents, mats, mosquito nets, blankets, solar lights, water and even food. This is the worst earthquake I've ever experienced," she said.
Like Nyo Nyo Lwin, thousands of families across Mandalay, Myanmar, are struggling to rebuild their lives amid the threat of diseases. Since April 20, China's 50-member public health team has been working around the clock in the region to prevent outbreaks in the aftermath of the devastating 7.9-magnitude earthquake that struck Myanmar on March 28.
The team has set up temporary labs, testing water, distributing supplies, and offering vaccination guidance. They've been active for over 20 consecutive days and plan to stay a few more, according to the team.
"We were living on the fourth floor," said 78-year-old U Aung Lwin, another earthquake survivor. "When the shaking started, I tried to stand but fell and hit my head on the bed. I got injured."
"The Red Cross Society of China came and disinfected our area. Donors gave us what we needed here," his wife Daw Aye added. "I'm grateful to the donors."
Ko Kyaw Lwin, 55, and three of his family members are sheltering in a China-donated tent. "Our apartment is unsafe now. Chinese doctors came, treated the water, and advised us to visit the health center for vaccination," he said.
"We've never seen an earthquake like this. The donations helped when we needed them the most. But we're worried about where we can go after we leave the shelter. Can we send our kids back to school?"
Official data showed that the earthquake has killed around 3,800 people, injured more than 5,100, and left approximately 100 missing as of May 9.
Chen Lei, head of the China Public Health Team to Myanmar and deputy director of the National Disease Control and Prevention Administration's emergency response department, said this mission is part of China's emergency humanitarian relief assistance to Myanmar. "Our team is an important manifestation of the health cooperation between the two countries," said Chen.
"By directly participating in on-site health and epidemic prevention work, we have conveyed China's mature post-disaster health and epidemic prevention experience and practices to Myanmar, provided post-disaster epidemic prevention technical solutions on time, and effectively carried out technical training including laboratory testing, environmental disinfection, and post-disaster epidemic prevention, which helped improve Myanmar's ability to respond to public health emergencies and built a solid line of defense for regional public health security," Zhao Shiwen, deputy director of the Yunnan Center for Disease Control and Prevention, said.
Zhang Bike, deputy director of the Institute of Infectious Disease Control and Prevention at the Chinese Center for Disease Control and Prevention, said the team has conducted three rounds of visits to key disaster sites in Mandalay.
Their efforts have included vector control, environmental disinfection, health education, psychological support, and vaccination guidance.
Zhang added that the team has worked closely with local health institutions to develop 12 technical documents to aid Myanmar's post-disaster health response, trained 67 local health professionals, and continues to provide support such as water quality testing and psychological assistance to both local communities and Chinese companies.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
10 hours ago
- The Star
Father's Day reminder: EcoWaste warns about risky supplements for men
MANILA: Environmental group EcoWaste Coalition has warned the public about sexual enhancement and energy products in sidewalk stalls, Chinese drug stores and online sellers that pose serious health risks to men, as the country celebrates Father's Day. In a statement on Sunday (June 15), the group pointed out that these products lack authorisation for sale and may contain potent ingredients that could have serious side effects, according to health authorities in the Philippines, as well as the United States and Canada. 'Many products that claim to help with sexual enhancement or treat sexual dysfunction – such as male enhancement supplements, erectile dysfunction treatments, male energy pills, and stamina pills – are likely to be contaminated with dangerous hidden ingredients. These contaminated products are a type of medication health fraud,' the EcoWaste said, citing the US Food and Drug Administration. 'These products are sometimes falsely advertised as dietary supplements, food and/or all-natural treatments. They often have multiple positive reviews and/or are being shared through social media. These products pose serious health risks and are not guaranteed to work. They can lead to severe health issues and hospitalisation,' it added. EcoWaste said some of the ingredients of the product should only be consumed under the supervision of a healthcare professional, some of the products also contain contents not included in label, 'such as prescription drugs sildenafil and/or tadalafil possibly at doses exceeding maximum recommended amounts.' Citing the FDA, the group explained that 'sildenafil citrate is a prescription drug used to treat erectile dysfunction in males and is prohibited in food supplements due to potential health risks, particularly for persons who have had a stroke, those with cardiovascular diseases, kidney problems, and low blood pressure.' 'Possible side effects of consuming sexual enhancement or energy products with sildenafil citrate include changes in vision or sudden vision loss, diarrhea, dizziness, headache, indigestion, nasal congestion, urinary tract infection, and priapism,' it added, quoting the FDA said. Similarly, tadalafil is a prescription drug used to treat male sexual problems but poses side effects to individuals who have had a stroke, as well as blood, heart, kidney and stomach ulcer problems. In line with this, the group advised the public to avoid buying unregistered products and instead consult a health professional before buying or consuming such products. - Philippine Daily Inquirer/ANN


Borneo Post
20 hours ago
- Borneo Post
Made-in-China brain tech sparks hope for children with autism
Photo taken on June 6, 2025 shows the therapeutic equipment developed by Chengdu Xinnao Technology Co Ltd in Chengdu. – Xinhua photo CHENGDU (June 15): In a sunlit therapy room at Chengdu Xinnao Technology Co Ltd in southwest China's Sichuan Province, a five-year-old boy surnamed Chen bursts into giggles as his favorite cartoon character waves back, a response triggered by brain signals decoded through his headset. A moment that might seem ordinary for most children feels like a miracle to Chen's family from Gansu Province, and a profound relief for Feng Rui, founder of the high-tech company dedicated to harnessing brain-computer interface (BCI) technology for autism intervention. China's 13 million people diagnosed with autism spectrum disorder (ASD), as reported by the China Disabled Persons' Federation in 2023, face a harsh reality. Most receive little to no standardised therapy due to a shortage of specialists and the high cost of treatment. Feng, a 45-year-old bioengineer turned entrepreneur, is determined to change this equation. He likens the brain's neural networks to a sprawling highway system. 'In children with autism, some 'routes' are disconnected, others congested with excessive signals. This disrupts their ability to process social cues, language, and sensory inputs,' he explained. These biological roadblocks, long obscured by the brain's complexity, have confounded global efforts to address both early diagnosis and the development of effective, accessible treatment, Feng said. Worldwide, about 80 million people with ASD live with a condition where traditional therapies often require years of costly behavioral training, with results that frequently diminish over time, Feng noted, adding that his team is working to address the root cause by targeting irregular neural pathways in the brain. Co-developed with researchers from the Chengdu-based University of Electronic Science and Technology of China (UESTC), their approach focuses on identifying autism-specific biomarkers in neural activity through noninvasive, AI-driven analysis. Key to this innovation is a diagnostic headset, the Quick-20r, equipped with 19 flexible electrodes that map brainwaves in real time. 'Unlike traditional wet EEG (electroencephalogram) systems requiring gel and clinical settings, our dry sensors capture neural 'traffic patterns' as children engage with tasks,' Feng said. These signals feed into algorithms combining deep learning and neuroimaging to detect disrupted circuits linked to social communication. The headset achieves 91.67 per cent diagnostic accuracy without the discomfort of traditional conductive gels, Feng said. 'For toddlers as young as two, this ease of use is critical.' A Transcranial Magnetic Stimulation device, resembling an infinity symbol, uses AI to map abnormal neural circuits before delivering targeted magnetic pulses to recalibrate those pathways. 'Think of it as performing precision road repairs on faulty neural highways. In the end, it's like tuning the brain to restore harmony in chaotic neural orchestras,' Feng said. The toolkit has already served over 2,000 children worldwide. 'After treatment, we've observed significant changes in the amygdala structure on the right side of the children's brains, with alterations in functional networks as well,' Feng added. In addition to leveraging these technological devices, Feng's team integrates traditional treatment methods to develop a complete solution. Next to their instruments, the company has set up several therapy rooms where staff provide additional treatments using language, social interaction, and music for children with autism. Tech wins, love conquers Recalling his career, Feng said the turning point came during a 2021 charity event for the International Day of Persons with Disabilities. At that time, his team offered a free month-long treatment to 30 children with autism, with many showing significant improvements in social interaction and communication halfway through the treatment cycle. However, the parents collectively voiced their concerns: 'If there are no fees, what will happen to future treatments?' and 'Will we be abandoned after this?' 'Their trust and concerns propelled us to industrialise the technology,' said Feng, who established his company in 2022 with government backing. Feng underlined that Chengdu's unique blend of academic resources – from UESTC's engineering prowess to renowned West China Hospital of Sichuan University's clinical expertise – has created fertile ground for BCI development. Municipal support goes beyond funding, with local governments actively linking innovators to healthcare institutions, while recent matchmaking events in Beijing have opened doors to national collaborations. Recognised as a national outstanding case of technology-assisted disability support by the China Disabled Persons' Federation, the BCI technology for autism intervention now operates in over 30 hospitals nationwide. With treatments effective for 80 per cent of patients, Feng aims to develop therapies for ADHD (attention deficit hyperactivity disorder) and depression next. At the same time, his devices are being shown alongside big tech companies' products at innovation events in Chengdu, highlighting their importance beyond just healthcare. 'Brain-computer interfaces could change how smart cities and education work,' he said, stressing that for now, the main focus is on improving autism treatment. 'We are also establishing the largest brain network database for age-appropriate children nationwide, which places us at the forefront in the industry,' he added. Looking back on the years of work, Feng said this spring has been the most memorable, filled with good news from the children receiving treatment. A Swedish boy who had shown little progress with European therapies spoke his first word – 'Mama' – after completing a treatment cycle developed by Feng's company. Another six-year-old Japanese boy moved from relying on sedation to sleeping naturally within weeks; meanwhile, a girl from Lanzhou in northwest China is now navigating friendships at elementary school, milestones that once seemed out of reach for children labeled 'untreatable'. 'Every brain's wiring is unique, but love and patience are always a way of connecting minds,' Feng said. – Xinhua autism China treatment Xinhua


Malaysian Reserve
2 days ago
- Malaysian Reserve
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ — Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. 'This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China,' said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. 'Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes.' 'Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models.' said Dr. Yu Dehua, CEO at USKbio. 'This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region.' The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: